D0431 is the CDT code for an adjunctive pre-diagnostic test for detecting mucosal abnormalities, including oral cancer screening. It covers technology-assisted screening aids used alongside a standard clinical oral examination. Per the CDT descriptor, this code does not replace cytology or biopsy procedures. It is classified as a supplemental diagnostic tool, not a definitive diagnostic test.
Last updated June 2026 ยท Reviewed by the PracticeAlpha billing team
Get help with D0431 claims →Patients with a history of tobacco or alcohol use, previous oral mucosal lesions, or a personal or family history of oral cancer are candidates for adjunctive screening as part of routine recall visits. The test supplements the standard clinical examination.
When a clinical exam identifies a lesion, discoloration, or mucosal change that warrants closer evaluation, an adjunctive screening technology can help characterize the finding and support the decision about whether further investigation such as biopsy is needed.
D0431 applies to fluorescence-based visualization devices and similar adjunctive technologies cleared by the FDA for use in identifying mucosal abnormalities. The device must be used in addition to, not instead of, the standard oral mucosal examination.
Do NOT use D0431 for: The standard visual oral cancer screening that is part of a comprehensive or periodic exam (covered under D0150 or D0120). Oral cytology brush biopsy (separate CDT code). Tissue biopsy or incisional biopsy (separate CDT codes). Routine exams without an adjunctive screening device being used. The CDT descriptor requires a specific adjunctive test, not just a thorough visual exam.
Many dental insurance plans have not added D0431 to their covered benefit schedules. If the payer does not list the code, the claim will be denied as a non-covered service. Before offering the adjunctive screening, verify with the patient's plan whether D0431 is a recognized benefit. Patients may need to pay out of pocket if their plan excludes it.
Some payers bundle D0431 into the exam code and consider it already included in D0120 or D0150. If bundled, the payer pays only the exam fee. Documentation showing that the adjunctive device is a distinct procedure beyond the standard visual exam may support an appeal, but not all plans will reverse a bundling decision.
The claim must be supported by a note identifying that a specific adjunctive screening technology was used, not just a thorough visual oral cancer exam. If the record only notes "oral cancer screening performed," a payer reviewing the claim may consider that the standard exam-inclusive screening, not the adjunctive test D0431 describes.
Plans that do cover D0431 may limit frequency. Some tie coverage to annual recall visits or to patient risk factors. If billed more frequently than the plan allows or without a documented clinical reason, the claim will be denied. Check frequency limits when verifying benefits.
Record the name or type of adjunctive screening technology used, for example a fluorescence visualization device. This distinguishes D0431 from the standard clinical oral cancer exam. The device name in the note connects the service to the CDT code.
Document the basis for performing the test: patient risk factors such as tobacco or alcohol use, a specific clinical finding observed during the exam, or an established protocol for high-risk patients. Routine use without clinical context makes the claim harder to defend on appeal.
Record what the adjunctive screening showed: normal findings, areas of altered fluorescence, or findings that prompted further evaluation. Documenting a result closes the loop and demonstrates the test had diagnostic value.
The clinical note should make clear that the adjunctive test was performed in addition to the standard visual and tactile oral mucosal exam, not as a substitute for it. The CDT descriptor requires this distinction.
If the adjunctive screening identified anything requiring follow-up, document the plan: observation with recall, referral, cytology, or biopsy. This is important for clinical and medicolegal purposes, and it reinforces that the test was clinically indicated.
Diagnostic and preventive codes getting denied or written off? We audit your billing patterns and recover revenue that should not be left on the table.
Learn about our billing servicesD0431 is the CDT code for an adjunctive pre-diagnostic test for detecting mucosal abnormalities, including oral cancer screening. It covers technology-assisted screening aids used in addition to the standard clinical oral examination. The CDT descriptor states it is not a replacement for cytology or biopsy procedures.
D0431 covers adjunctive screening technologies such as fluorescence-based visualization devices and chemiluminescent illumination systems. These are used to help identify mucosal changes that may not be visible under standard light. The device must be used alongside, not instead of, the standard clinical oral cancer exam.
Coverage varies widely. Some plans include D0431 as a diagnostic or preventive benefit. Many plans do not have it in their fee schedule and will deny it as a non-covered service. Verify with the patient's specific plan before performing the service.
D0431 can be billed on the same date as D0120 or D0150, as it is a distinct adjunctive service beyond the standard visual exam. Some payers may bundle it. Documentation distinguishing the adjunctive test from the exam-included oral cancer screening is important for supporting separate billing.
D0120 and D0150 include a standard visual and tactile oral cancer screening as part of the examination. D0431 covers a technology-assisted adjunctive test that goes beyond the standard visual exam. They are separate procedures, and the clinical record should document both distinctly.
No. The CDT descriptor explicitly states that D0431 does not replace cytology or biopsy procedures. If a suspicious lesion requires a biopsy or cytology sample, those are separate procedures billed under their own CDT codes.
Search all CDT codes in our dental coding guide.